TaiMed Biologics

Focus: TaiMed Biologics is a Taiwan-based public biotechnology company focused on biologics, small molecules, and antibody-drug conjugates (ADCs) with a concentrated pipeline in HIV and infectious diseases. The company operates as a mid-cap biotech with multiple programs across Phase 1–3 development.

Infectious Diseases

Profile data last refreshed 31m ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About TaiMed Biologics

AI assessmentNot Hiring

No open roles listed right now. Follow TaiMed Biologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

TMB-607

Human Immunodeficiency Virus

Phase 1

Clinical Trials (1)

NCT03110549Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Phase 1

Help build intelligence for TaiMed Biologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified modality expertise across monoclonal antibodies, small molecules, and ADCs—rare combination for specialized skill development.
Advancing late-stage HIV assets (ibalizumab in Phase 3) with near-term regulatory catalysts and commercial upside.
Public company status provides equity upside potential and structural stability versus early-stage private biotech.

Watch Out For

Currently zero active job postings signal limited near-term hiring demand or organizational headcount constraints.
Single therapeutic focus (infectious diseases/HIV) limits career optionality if pipeline pivots or stalls.
Sparse public disclosure on financials, headcount, and recent milestones creates visibility gaps for due diligence.

Generated by Claude from TaiMed Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TMB-365

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT04027387Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

Phase 1

ibalizumab

Prevention of Infection With HIV-1

Phase 1

Clinical Trials (1)

NCT01292174Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

Phase 1